ProMIS Neurosciences announced that PMN 310, a monoclonal antibody (mAb), has been designated its first lead product for development in Alzheimer's disease (AD). The neuroprotective effect of PMN 310 was investigated at a well recognized contract research organization (CRO) specializing in neurodegenerative diseases. Injection of prion-like forms of A (also called toxic oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called novel object recognition. Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, oligomer-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN 310 to mice completely prevented the loss of short-term memory formation caused by toxic oligomers.